Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Brunswick Group hired former Pfizer China government affairs vice-president Xi Qing as a partner in Asia....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...He no longer owns Idol and five years ago sold his company, 19 Entertainment, to media group CKX Inc....
...Tyler Brûlé is editor-in-chief of Monocle tyler.brule@ft.com More columns at www.ft.com/brule...
...Much debate in the blogosphere on Thursday about “Pimco versus Barclays” – or rather, “Bill Gross v Tim Bond” following the FT’s publication of a distinctly bullish piece by Tim Bond, head of asset allocation...
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...” - Pfizer has bet $4.5bn that it can count on the banks to lend. - “Fannie Mae to ask for up to $16bn” - The TARP-linked index: “not looking good” - “Quelle surprise!...
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
International Edition